^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ICX-101

i
Other names: ICX-101
Company:
Incurix
Drug class:
MYC inhibitor
over1year
ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression (AACR 2023)
ICX-101 is a potent MYC inhibitor that shows antitumor activity in lung cancer PDCs. Our results suggest the potential of ICX-101 as a possible therapeutic option in advanced lung cancer with high MYC expressions.
Clinical • Metastases
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC expression
|
ICX-101